313.13MMarket Cap-6285P/E (TTM)
11.885High11.495Low106.39KVolume11.560Open11.410Pre Close1.24MTurnover0.55%Turnover RatioLossP/E (Static)26.96MShares24.00052wk High1.74P/B224.35MFloat Cap7.91052wk Low--Dividend TTM19.32MShs Float24.000Historical High--Div YieldTTM3.42%Amplitude7.910Historical Low11.616Avg Price1Lot Size
Alto Neuroscience Stock Forum
NEWS
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
ALTO-101 demonstrated favorable pharmacokinetic and tolerability profile in Phase 1 study
Transdermal formulation provided significantly greater drug exposure with fewer adverse events
Proof-of-concept study for CIAS to start in the first half of 2024
Topline data expected in the second half of 2025
Achievement of target exposure with propri...
No comment yet